Dr. Soo-Min Lee is the CTO and Head of the Research Center at Samjin Pharmaceutical. He holds a bachelor’s degree in Animal Science and a master’s degree in Molecular Biology from Seoul National University, followed by a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine. Before joining Samjin in March 2022, Dr. Lee spent 18 years at SK Chemicals, where he focused on new drug development, AI platform development, collaborative research, and investment management. In 2019, he led the Open Innovation team, forging partnerships with AI-driven drug discovery firms and biotech ventures to advance drug development. At Samjin, Dr. Lee has strengthened the company’s research infrastructure and expanded its drug pipeline, particularly in immuno-oncology and immunology. He also established task forces for Digital Innovation and Antibody-Drug Conjugates (ADC), integrating AI technologies into research processes. He expanded collaborative efforts, partnering with companies specializing in AI-driven drug discovery, like Cyclica and Insilico, and ADC cancer therapies. His leadership focuses on efficient drug development by prioritizing high-potential projects while discontinuing less promising ones to enhance research efficiency.